Therapeutic Targeting of Senescent Cells in Lupus
Targeting senescent cells in patients with lupus presents a potential novel approach to disease management and improved clinical outcomes. While it is known that lupus patients possess cells with a senescence-like phenotype, it is unknown whether these cells would respond to available senolytic drugs. Studying the effects of these drugs in vitro using patient and lupus mouse model samples will further fundamental insights into the potential role of senolytic drugs in the treatment of lupus.
Richard J. Looney, M.D.
Principal Investigator
Publications
View All Publications- Farm exposure in infancy is associated with elevated systemic IgG4, mucosal IgA responses, and lower incidence of food allergy.; Science translational medicine; Vol 17(828), pp. eads1892. 2025 Dec 10.
- Differences in outcomes associated with ABO blood groups in recipients of IVIG.; Blood vessels, thrombosis & hemostasis; Vol 2(3), pp. 100075. 2025 May 09.
- A Phenotypically Distinct Human Th2 Cell Subpopulation Is Associated With Development of Allergic Disorders in Infancy.; Allergy. 2025 Feb 03.
- Human milk antibodies to global pathogens reveal geographic and interindividual variations in IgA and IgG.; The Journal of clinical investigation; Vol 134(15). 2024 Jun 11.
February 6, 2026
Dr. Katherine Herman Presents Medical Grand Rounds
January 23, 2026
Dr. Theresa Bingemann Presents at the AAAAI Program Directors Assembly Winter Meeting
November 21, 2025
Dr. Rangel-Moreno an International Speaker at the Research Seminars in Biological Sciences and International Biomedicine Workshop
October 22, 2025
Dr. Jennifer Anolik Presents at Upstate Medical Center Symposium
October 20, 2025
National Scleroderma Foundation Rochester Education Forum Held at URMC
Contact Us
Looney Lab
601 Elmwood Ave/Box 695
Rochester, NY 14642